Eagle Pharmaceuticals (EGRX) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) recently:

  • 3/5/2019 – Eagle Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 3/1/2019 – Eagle Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 3/1/2019 – Eagle Pharmaceuticals was given a new $66.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 2/28/2019 – Eagle Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $58.00 price target on the stock. They wrote, “. Post 4Q18, we are reiterating our Neutral rating and our 12- month price target on EGRX shares of $58. Pipeline setbacks in 2018 have created an overhang on the visibility of near term growth drivers for EGRX, which keeps us on the sidelines for now. Given the current visibility, we believe EGRX stock remains fairly valued at current levels. That said EGRX’s current business continues to perform well and the company is advancing Ryanodex for nerve agent exposure and acute radiation syndrome, both of which we believe have the potential to get into the strategic national stockpile, if successful.””
  • 2/23/2019 – Eagle Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/22/2019 – Eagle Pharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 2/18/2019 – Eagle Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 2/14/2019 – Eagle Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $44.00 price target on the stock. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 2/13/2019 – Eagle Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 2/5/2019 – Eagle Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 2/1/2019 – Eagle Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $47.00 price target on the stock. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 1/29/2019 – Eagle Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 1/18/2019 – Eagle Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $49.00 price target on the stock. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

Shares of Eagle Pharmaceuticals stock opened at $47.33 on Friday. Eagle Pharmaceuticals Inc has a 12-month low of $36.03 and a 12-month high of $85.66. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.13 and a quick ratio of 3.92. The stock has a market capitalization of $659.02 million, a price-to-earnings ratio of 22.65 and a beta of 1.73.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.04. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The company had revenue of $56.05 million during the quarter, compared to analysts’ expectations of $54.17 million. During the same period last year, the company posted $1.05 earnings per share. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, sell-side analysts predict that Eagle Pharmaceuticals Inc will post 3.43 earnings per share for the current year.

In other news, CEO Scott Tarriff sold 30,085 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $41.54, for a total transaction of $1,249,730.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 86,082 shares of company stock valued at $3,746,371. Corporate insiders own 28.20% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of EGRX. Capital Impact Advisors LLC grew its stake in Eagle Pharmaceuticals by 40.9% in the 4th quarter. Capital Impact Advisors LLC now owns 33,939 shares of the specialty pharmaceutical company’s stock worth $1,331,000 after acquiring an additional 9,855 shares during the period. Geode Capital Management LLC grew its stake in Eagle Pharmaceuticals by 10.7% in the 4th quarter. Geode Capital Management LLC now owns 132,043 shares of the specialty pharmaceutical company’s stock worth $5,319,000 after acquiring an additional 12,748 shares during the period. Norges Bank purchased a new stake in Eagle Pharmaceuticals in the 4th quarter worth approximately $10,948,000. Dimensional Fund Advisors LP grew its stake in Eagle Pharmaceuticals by 58.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 131,605 shares of the specialty pharmaceutical company’s stock worth $5,302,000 after acquiring an additional 48,359 shares during the period. Finally, Public Employees Retirement System of Ohio grew its stake in Eagle Pharmaceuticals by 415.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 8,360 shares of the specialty pharmaceutical company’s stock worth $337,000 after acquiring an additional 6,738 shares during the period. 92.54% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

See Also: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Eagle Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.